Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2026

Conditions
Epithelial Ovarian CancerEfficacySafetyBone Mineral DensityTolerability
Interventions
DRUG

Fluzoparib

The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.

DRUG

Apatinib Mesylate

The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV

NCT06539091 - Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | Biotech Hunter | Biotech Hunter